Arcutis Biotherapeutics and Sato Pharmaceutical Collaborate for Skin Treatment Development in Japan
Strategic Collaboration for Topical Roflumilast in Japan
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, has secured a strategic collaboration and licensing agreement with Sato Pharmaceutical Co., Ltd. The partnership focuses on developing and commercializing topical roflumilast, a non-steroidal treatment for inflammatory skin diseases in Japan. This collaboration includes upfront and milestone payments, as well as royalties.
Development of Roflumilast for Skin Conditions
Roflumilast, a potent phosphodiesterase type 4 (PDE4) inhibitor, is under development in cream and foam formulations for conditions like plaque psoriasis, seborrheic dermatitis, and atopic dermatitis. Sato holds an exclusive license for these formulations in Japan and will oversee their development, manufacture, and commercialization.
Enthusiasm for Market Expansion
Arcutis’ President and CEO, Frank Watanabe, expresses excitement about the collaboration with Sato and their shared commitment to improving patient lives. Sato’s President and CEO, Seiichi Sato, is optimistic about the impact on individuals with immune-mediated skin diseases in Japan.
Continued Development in Global Markets
Arcutis will continue to manage the development and commercialization of roflumilast cream and foam in the US and other regions, excluding Greater China and Southeast Asia. With FDA-approved products and ongoing clinical programs, Arcutis aims to address various dermatological conditions.
Safety Information and Treatment Options
The safety profile for ZORYVE cream and foam includes contraindications for patients with moderate to severe liver impairment. Common adverse reactions and precautions are also outlined to ensure safe use of the treatment.
Enhancing Treatment Options for Patients
This strategic collaboration between Arcutis and Sato aims to provide a novel treatment option for Japanese patients with dermatological conditions. The partnership reflects Arcutis’ dedication to meeting the needs of individuals living with skin diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
